Karyopharm: "Hold" Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI)
Seeking Alpha
Last updated: July 22, 2026
Karyopharm (KPTI) has been downgraded to a "Hold" rating due to a combination of factors including disappointing U.S. sales of its drug XPOVIO, setbacks with the U.S. Food and Drug Administration (FDA), and inconclusive data from the SENTRY trial. Despite these challenges, the company maintains confidence in achieving its 2026 milestones.
- Key Facts: The primary driver for the downgrade is the weaker-than-expected sales performance of XPOVIO in the United States.
- The company has encountered difficulties and setbacks with the FDA, which have likely impacted its development and commercialization strategies.
- Results from the SENTRY clinical trial have been described as mixed, suggesting that the data did not provide a clear or overwhelmingly positive outcome for XPOVIO.
- Despite the current headwinds, Karyopharm's management remains optimistic about reaching its important development and business objectives scheduled for the year 2026.
- The downgrade to "Hold" suggests a period of cautious observation for investors, balancing current challenges with potential future upside.
